XOMAP | XOMA Corporation Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	25.60 - 25.60
52 Week Range	21.40 - 26.48
Beta	N/A
Implied Volatility	N/A
IV Rank	N/A
Day's Volume	187
Average Volume	1,675
Shares Outstanding	13,241,959
Market Cap	338,994,150
Sector	Healthcare
Industry	Biotechnology
IPO Date	2020-12-16

Valuation
Profitability
Growth
Health
P/E Ratio	25.57
Forward P/E Ratio	N/A
EPS	1.00
1YR Price Target	N/A
Dividend Yield	8.43%
Dividend Per Share	2.16
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	13
Country	USA
Website	XOMAP

XOMA Corporation operates as a biotechnology royalty aggregator in Europe, the United States, and the Asia Pacific. The company engages in helping biotech companies for enhancing human health. It acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceutical or biotechnology companies. The company focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners. It has a portfolio with approximately 70 assets. XOMA Corporation was incorporated in 1981 and is headquartered in Emeryville, California.

XOMAP's peers: POWWP, STRRP, XOMAO, FBIOP, FRGAP, OTRKP, RILYP

*Chart delayed

Analyzing fundamentals for XOMAP we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is very good and Health is very weak. For more detailed analysis please see XOMAP Fundamentals page.

Watching at XOMAP technicals we can see that long-term trend is bullish, the same as bullish middle-term trend, as well as bullish short-term trend. More technicals details can be found on XOMAP Technicals page.